Figure 2.
(A) Cumulative incidence of non-relapse mortality (p = 0.04) and (B) progression-free survival (p < 0.001) as stratified by pretransplant HCT-CI among patients with lymphoma, CLL, and multiple myeloma. (From Farina et al., 2009.57 Reprinted with permission. ©2009 Macmillan Publishers, Ltd.)
